Literature DB >> 2926324

Vaccination with the major secretory protein of Legionella pneumophila induces cell-mediated and protective immunity in a guinea pig model of Legionnaires' disease.

S J Blander1, M A Horwitz.   

Abstract

We have examined the capacity of the major secretory protein (MSP) of Legionella pneumophila to induce humoral, cell-mediated, and protective immunity in a guinea pig model of Legionnaires' disease. MSP was purified to homogeneity by ammonium sulfate precipitation, molecular sieve chromatography, and ion-exchange chromatography. The purified MSP was nonlethal and nontoxic to guinea pigs upon subcutaneous administration. Guinea pigs immunized with a sublethal dose of aerosolized L. pneumophila or a subcutaneous dose of MSP developed a strong cell-mediated immune response to MSP. Such guinea pigs exhibited marked splenic lymphocyte proliferation and cutaneous delayed-type hypersensitivity to MSP in comparison with control animals. Guinea pigs immunized with MSP also developed a strong humoral immune response to MSP, as assayed by an ELISA. The median reciprocal antibody titer was 362 (range 45 to greater than 2,048) for immunized animals compared with less than 8 for controls. In contrast, guinea pigs immunized with a sublethal dose of L. pneumophila failed to develop anti-MSP antibody. Guinea pigs immunized with MSP and then challenged with a lethal aerosol dose of L. pneumophila exhibited highly significant protective immunity in each of five consecutive experiments. MSP induced protective immunity in dose-dependent fashion (40 greater than 10 greater than 2.5 greater than 0.6 micrograms MSP); vaccination with two doses of as little as 2.5 micrograms MSP induced significant protective immunity (p = 0.01, Fisher's Exact Test, two-tailed). Altogether, 21 (81%) of 26 animals immunized with 40 micrograms MSP survived challenge compared with 0 (0%) of 26 sham-immunized control animals (p = 7 x 10(-10), Fisher's Exact Test, two-tailed). MSP-immunized but not control guinea pigs were able to limit L. pneumophila multiplication in their lungs. This study demonstrates that (a) guinea pigs sublethally infected with L. pneumophila develop a strong cell-mediated immune response to MSP; (b) guinea pigs immunized with MSP develop a strong humoral and cell-mediated immune response to MSP; (c) guinea pigs immunized with MSP develop a very high level of protective immunity to lethal aerosol challenge with L. pneumophila; and (d) MSP-immunized animals are able to limit L. pneumophila multiplication in their lungs. MSP, an extracellular protein of an intracellular pathogen, has potential as a vaccine for the prevention of Legionnaires' disease. Secretory molecules of other intracellular pathogens may also have vaccine potential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2926324      PMCID: PMC2189286          DOI: 10.1084/jem.169.3.691

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  Studies on hypersensitivity. II. Delayed hypersensitivity to denatured proteins in guinea pigs.

Authors:  P G GELL; B BENACERRAF
Journal:  Immunology       Date:  1959-01       Impact factor: 7.397

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Electron microscopic examination of the inflammatory response to Legionella pneumophila in guinea pigs.

Authors:  S M Katz; S Hashemi
Journal:  Lab Invest       Date:  1982-01       Impact factor: 5.662

4.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

5.  The kinetics of early inflammatory events during experimental pneumonia due to Legionella pneumophila in guinea pigs.

Authors:  G S Davis; W C Winn; D W Gump; H N Beaty
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

6.  Reactivity of serum from patients with suspected legionellosis against 29 antigens of legionellaceae and Legionella-like organisms by indirect immunofluorescence assay.

Authors:  H W Wilkinson; A L Reingold; B J Brake; D L McGiboney; G W Gorman; C V Broome
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

7.  Biological activity of protein antigens isolated from Mycobacterium tuberculosis culture filtrate.

Authors:  F M Collins; J R Lamb; D B Young
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

8.  Characterization of avirulent mutant Legionella pneumophila that survive but do not multiply within human monocytes.

Authors:  M A Horwitz
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

9.  Immune responses against native and chemically modified albumins in mice. I. Analysis of non-thymus-processed (B) and thymus-processed (T) cell responses against methylated bovine serum albumin.

Authors:  V Schirrmacher; H Wigzell
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

10.  Interaction of the legionnaires' disease bacterium (Legionella pneumophila) with human phagocytes. II. Antibody promotes binding of L. pneumophila to monocytes but does not inhibit intracellular multiplication.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

View more
  35 in total

1.  Legionella pneumophila contains a type II general secretion pathway required for growth in amoebae as well as for secretion of the Msp protease.

Authors:  L M Hales; H A Shuman
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 3.  Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.

Authors:  A Tärnvik; M Eriksson; G Sandström; A Sjöstedt
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

Review 4.  Molecular pathogenesis of infections caused by Legionella pneumophila.

Authors:  Hayley J Newton; Desmond K Y Ang; Ian R van Driel; Elizabeth L Hartland
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

5.  Identification, recombinant expression, immunolocalization in macrophages, and T-cell responsiveness of the major extracellular proteins of Francisella tularensis.

Authors:  Bai-Yu Lee; Marcus A Horwitz; Daniel L Clemens
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis.

Authors:  M A Horwitz; B W Lee; B J Dillon; G Harth
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Authors:  Qingmei Jia; Richard Bowen; Bai-Yu Lee; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Vaccine       Date:  2016-08-28       Impact factor: 3.641

8.  Molecular and biochemical characterization of a protective 40-kilodalton antigen from Corynebacterium pseudotuberculosis.

Authors:  M J Wilson; M R Brandon; J Walker
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

9.  Humoral immunity through immunoglobulin M protects mice from an experimental actinomycetoma infection by Nocardia brasiliensis.

Authors:  Mario C Salinas-Carmona; Isabel Pérez-Rivera
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  Genetic, immunological, and cytotoxic comparisons of Legionella proteolytic activities.

Authors:  F D Quinn; M G Keen; L S Tompkins
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.